

May 15, 2025

Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

Company name: JEOL Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 6951
 URL: <https://www.jeol.co.jp>
 Representative: Izumi Ooi, President & CEO
 Inquiries: Toshihiko Kanayama, Director & Officer; General Manager, Management Strategy Planning Division
 Telephone: +81-42-543-1111
 Scheduled date of annual general meeting of shareholders: June 26, 2025
 Scheduled date to commence dividend payments: June 27, 2025
 Scheduled date to file annual securities report: June 25, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and securities analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2025	196,695	12.8	35,501	28.9	34,424	14.7	18,688	(13.9)
March 31, 2024	174,336	7.2	27,531	14.0	30,023	27.8	21,704	21.7

Note: Comprehensive income For the fiscal year ended March 31, 2025: ¥16,789 million [(38.0)%]
 For the fiscal year ended March 31, 2024: ¥27,099 million [40.7%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
March 31, 2025	365.55	-	14.3	15.2	18.0
March 31, 2024	424.92	-	19.1	14.0	15.8

Reference: Share of profit (loss) of entities accounted for using equity method
 For the fiscal year ended March 31, 2025: ¥353 million
 For the fiscal year ended March 31, 2024: ¥88 million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2025	222,486	136,653	61.4	2,672.19
March 31, 2024	230,213	125,513	54.5	2,457.01

Reference: Equity
 As of March 31, 2025: ¥136,653 million
 As of March 31, 2024: ¥125,513 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2025	23,104	(855)	(17,116)	34,605
March 31, 2024	15,301	(18,028)	(798)	29,807

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2024	-	33.00	-	69.00	102.00	5,244	24.0	4.6
Fiscal year ended March 31, 2025	-	44.00	-	62.00	106.00	5,449	29.0	4.1
Fiscal year ending March 31, 2026 (Forecast)		53.00		53.00	106.00		30.1	

Note: 1. Breakdown of dividends at the end of the fiscal year ending March 31, 2024: Ordinary dividend: 49.00 yen Commemorative dividend: 20.00 yen
2. The year-end dividend per share for the fiscal year ending March 31, 2025 has been changed from 48 yen to 62 yen. For details, please refer to the "Notice Concerning Dividend (Dividend Increase)" announced today (May 15, 2025).

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2025	78,500	(10.0)	10,000	(36.8)	10,400	(26.2)	7,700	(29.5)	150.61
Fiscal year ending March 31, 2026	181,000	(8.0)	24,000	(32.4)	24,500	(28.8)	18,000	(3.7)	352.09

* **Notes**

- (1) Significant changes in the scope of consolidation during the period: Yes
Newly included: 2 companies (Japan Superconductor Technology, Inc., JEOL HOLDING EUROPE SAS)
- (2) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None
- (3) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2025	51,532,800 shares
As of March 31, 2024	51,532,800 shares

- (ii) Number of treasury shares at the end of the period

As of March 31, 2025	393,904 shares
As of March 31, 2024	448,841 shares

- (iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2025	51,123,935 shares
Fiscal year ended March 31, 2024	51,079,186 shares

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2025	165,279	13.1	32,286	26.5	33,007	12.4	18,231	(13.9)
March 31, 2024	146,114	8.0	25,513	21.9	29,377	28.4	21,172	20.8

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
March 31, 2025	356.61	-
March 31, 2024	414.50	-

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2025	186,501	124,280	66.6	2,430.26
March 31, 2024	197,231	113,452	57.5	2,220.90

Reference: Equity

As of March 31, 2025: ¥124,280 million

As of March 31, 2024: ¥113,452 million

* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

(Cautions on forward-looking statements, etc.)

Forward-looking statements, such as earnings forecasts, contained in this material are based on judgments made by the Company and the Group based on information available to the Company and the Group at the time of publication, but include risks and uncertainties. Actual results may differ from forecasts due to various factors such as the economic environment surrounding the Company, market trends, and fluctuations in exchange rates.

(How to obtain supplementary explanatory materials for financial results)

The Company plans to hold a briefing for institutional investors and analysts on Friday, May 30, 2025. Supplementary financial results briefing materials will be posted on the Company's website after the date of the financial results briefing.

Consolidated balance sheet

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Assets		
Current assets		
Cash and deposits	31,504	36,144
Notes and accounts receivable - trade, and contract assets	56,034	51,717
Merchandise and finished goods	16,713	15,932
Work in process	54,336	55,599
Raw materials and supplies	5,761	5,486
Income taxes refund receivable	64	145
Consumption taxes refund receivable	3,276	3,065
Other	3,014	2,219
Allowance for doubtful accounts	(850)	(819)
Total current assets	169,854	169,492
Non-current assets		
Property, plant and equipment		
Buildings and structures	29,732	30,461
Accumulated depreciation	(19,831)	(20,852)
Buildings and structures, net	9,901	9,609
Machinery, equipment and vehicles	6,494	7,385
Accumulated depreciation	(4,361)	(5,667)
Machinery, equipment and vehicles, net	2,132	1,717
Tools, furniture and fixtures	26,945	29,761
Accumulated depreciation	(21,753)	(23,651)
Tools, furniture and fixtures, net	5,191	6,109
Land	3,831	3,952
Leased assets	3,835	4,680
Accumulated depreciation	(2,763)	(3,143)
Leased assets, net	1,071	1,536
Construction in progress	386	1,183
Total property, plant and equipment	22,515	24,108
Intangible assets		
Software	880	804
Leased assets	14	-
Goodwill	599	911
Other	775	2,060
Total intangible assets	2,270	3,776
Investments and other assets		
Investment securities	29,601	14,769
Deferred tax assets	3,699	8,500
Other	2,263	1,847
Allowance for doubtful accounts	(7)	(7)
Total investments and other assets	35,556	25,109
Total non-current assets	60,343	52,994
Deferred assets		
Share issuance costs	15	-
Total deferred assets	15	-
Total assets	230,213	222,486

	As of March 31, 2024	As of March 31, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	14,315	11,197
Electronically recorded obligations - operating	15,197	4,677
Current portion of long-term borrowings	6,943	4,413
Lease liabilities	490	574
Accounts payable - other	3,344	3,486
Income taxes payable	5,692	6,039
Accrued consumption taxes	258	455
Contract liabilities	35,035	34,035
Provision for bonuses	2,029	2,156
Other	4,792	5,958
Total current liabilities	88,100	72,995
Non-current liabilities		
Long-term borrowings	7,584	3,170
Lease liabilities	764	1,127
Deferred tax liabilities	219	223
Provision for retirement benefits for directors (and other officers)	20	51
Provision for share awards for directors (and other officers)	651	665
Retirement benefit liability	6,595	6,846
Asset retirement obligations	317	370
Other	445	384
Total non-current liabilities	16,599	12,838
Total liabilities	104,699	85,833
Net assets		
Shareholders' equity		
Share capital	21,394	21,394
Capital surplus	21,271	21,271
Retained earnings	73,284	86,163
Treasury shares	(847)	(688)
Total shareholders' equity	115,102	128,140
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	6,198	4,295
Deferred gains or losses on hedges	(151)	(1)
Foreign currency translation adjustment	3,207	2,843
Remeasurements of defined benefit plans	1,157	1,374
Total accumulated other comprehensive income	10,411	8,512
Total net assets	125,513	136,653
Total liabilities and net assets	230,213	222,486

Consolidated statement of income

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Net sales	174,336	196,695
Cost of sales	95,051	104,297
Gross profit	79,285	92,397
Selling, general and administrative expenses		
Research and development expenses	10,264	11,978
Other	41,489	44,917
Total selling, general and administrative expenses	51,754	56,896
Operating profit	27,531	35,501
Non-operating income		
Interest income	220	249
Dividend income	177	228
Insurance claim income	41	-
Revenue from acceptance of development services	151	130
Share of profit of entities accounted for using equity method	88	353
Foreign exchange gains	600	-
Subsidy income	1,332	-
Other	201	260
Total non-operating income	2,813	1,223
Non-operating expenses		
Interest expenses	88	120
Loss on sale of trade receivables	1	2
Loss on cancellation of insurance policies	41	49
Settlement payments	40	-
Foreign exchange losses	-	1,952
Other	149	174
Total non-operating expenses	321	2,300
Ordinary profit	30,023	34,424
Extraordinary income		
Gain on sale of non-current assets	171	26
Gain on sale of investment securities	7	2,789
Gain on sale of shares of subsidiaries and associates	24	-
Gain on step acquisitions	-	112
Total extraordinary income	204	2,928
Extraordinary losses		
Loss on sale of non-current assets	3	3
Loss on retirement of non-current assets	24	5
Loss on valuation of investment securities	124	12,381
Impairment losses	603	-
Total extraordinary losses	756	12,389
Profit before income taxes	29,471	24,962
Income taxes - current	8,414	10,070
Income taxes - deferred	(647)	(3,795)
Total income taxes	7,766	6,274
Profit	21,704	18,688
Profit attributable to owners of parent	21,704	18,688

Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Profit	21,704	18,688
Other comprehensive income		
Valuation difference on available-for-sale securities	2,250	(1,902)
Deferred gains or losses on hedges	(228)	149
Foreign currency translation adjustment	2,178	(398)
Remeasurements of defined benefit plans, net of tax	1,105	216
Share of other comprehensive income of entities accounted for using equity method	88	35
Total other comprehensive income	5,394	(1,898)
Comprehensive income	27,099	16,789
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	27,099	16,789
Comprehensive income attributable to non-controlling interests	-	-

Consolidated statement of changes in equity

Fiscal year ended March 31, 2024

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	21,394	21,271	55,117	(904)	96,878
Dividends of surplus			(3,547)		(3,547)
Profit attributable to owners of parent			21,704		21,704
Purchase of treasury shares				(0)	(0)
Disposal of treasury shares				57	57
Change in scope of equity method			9		9
Net changes in items other than shareholders' equity					-
Total changes during period	-	-	18,166	57	18,223
Balance at end of period	21,394	21,271	73,284	(847)	115,102

	Accumulated other comprehensive income					Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	3,947	76	940	51	5,017	101,895
Dividends of surplus					-	(3,547)
Profit attributable to owners of parent					-	21,704
Purchase of treasury shares					-	(0)
Disposal of treasury shares					-	57
Change in scope of equity method					-	9
Net changes in items other than shareholders' equity	2,250	(228)	2,266	1,105	5,394	5,394
Total changes during period	2,250	(228)	2,266	1,105	5,394	23,618
Balance at end of period	6,198	(151)	3,207	1,157	10,411	125,513

Consolidated statement of changes in equity

Fiscal year ended March 31, 2025

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	21,394	21,271	73,284	(847)	115,102
Dividends of surplus			(5,809)		(5,809)
Profit attributable to owners of parent			18,688		18,688
Purchase of treasury shares				(1)	(1)
Disposal of treasury shares				160	160
Net changes in items other than shareholders' equity					-
Total changes during period	-	-	12,878	159	13,038
Balance at end of period	21,394	21,271	86,163	(688)	128,140

	Accumulated other comprehensive income					Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	6,198	(151)	3,207	1,157	10,411	125,513
Dividends of surplus					-	(5,809)
Profit attributable to owners of parent					-	18,688
Purchase of treasury shares					-	(1)
Disposal of treasury shares					-	160
Net changes in items other than shareholders' equity	(1,902)	149	(363)	216	(1,898)	(1,898)
Total changes during period	(1,902)	149	(363)	216	(1,898)	11,139
Balance at end of period	4,295	(1)	2,843	1,374	8,512	136,653

Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Cash flows from operating activities		
Profit before income taxes	29,471	24,962
Depreciation	4,650	4,925
Amortization of goodwill	97	253
Increase (decrease) in provision for bonuses	141	94
Increase (decrease) in retirement benefit liability	(89)	145
Increase (decrease) in provision for retirement benefits for directors (and other officers)	3	8
Increase (decrease) in provision for share awards for directors (and other officers)	179	173
Loss (gain) on sale and retirement of non-current assets	(143)	(17)
Loss (gain) on sale of investment securities	(7)	(2,789)
Loss (gain) on valuation of investment securities	124	12,381
Loss (gain) on sale of shares of subsidiaries and associates	(24)	-
Loss (gain) on step acquisitions	-	(112)
Share of loss (profit) of entities accounted for using equity method	(88)	(353)
Subsidy income	(1,332)	(20)
Impairment losses	603	-
Interest and dividend income	(397)	(478)
Interest expenses	88	120
Loss on sales of notes and accounts receivable-trade	1	2
Decrease (increase) in trade receivables	(4,169)	4,423
Decrease (increase) in inventories	(7,559)	2,233
Increase (decrease) in trade payables	(3,971)	(13,855)
Increase/decrease in consumption taxes payable/consumption taxes refund receivable	1,233	356
Increase (decrease) in contract liabilities	2,997	(1,422)
Other, net	300	171
Subtotal	22,109	31,202
Interest and dividends received	428	480
Interest paid	(71)	(136)
Loss on sales of notes and accounts receivable-trade-paid	(1)	(2)
Income taxes refund (paid)	(7,183)	(9,772)
Subsidies received	20	1,332
Net cash provided by (used in) operating activities	15,301	23,104

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Cash flows from investing activities		
Decrease (increase) in time deposits	744	135
Purchase of investment securities	(15,736)	-
Proceeds from sale of investment securities	12	3,041
Purchase of shares of subsidiaries and associates	(22)	-
Proceeds from sale of shares of subsidiaries and associates	24	-
Purchase of property, plant and equipment	(3,243)	(2,960)
Proceeds from sale of property, plant and equipment	212	96
Purchase of intangible assets	(232)	(1,303)
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-	(637)
Proceeds from collection of long-term loans receivable	-	2
Payments for acquisition of businesses	-	(150)
Other, net	211	919
Net cash provided by (used in) investing activities	(18,028)	(855)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-	(3,900)
Proceeds from long-term borrowings	8,000	-
Repayments of long-term borrowings	(4,739)	(6,943)
Redemption of bonds	(204)	-
Purchase of treasury shares	(0)	(1)
Dividends paid	(3,542)	(5,797)
Other, net	(311)	(474)
Net cash provided by (used in) financing activities	(798)	(17,116)
Effect of exchange rate change on cash and cash equivalents	1,329	(334)
Net increase (decrease) in cash and cash equivalents	(2,197)	4,797
Cash and cash equivalents at beginning of period	32,004	29,807
Cash and cash equivalents at end of period	29,807	34,605

(Notes on segment information, etc.)
Segment Information

1 Overview of Reporting Segments

The Group's reporting segments are those of the constituent units of the Group for which separate financial information is available and are subject to periodic review by the Board of Directors in order to determine the allocation of management resources and evaluate business performance.

The Group has three reporting segments: the Scientific and Metrology Instruments Segment, the Industrial Equipment Segment, and the Medical Equipment Segment, based on the classification of the Group's products according to the applications in which they are used.

The Scientific and Metrology Instruments segment manufactures and sells electron microscopes, nuclear magnetic resonance spectrometers, mass spectrometers, and other products. The Industrial Equipment segment manufactures and sells electron beam lithography system, electron beam metal AM machine (3D Printer), and high-frequency power supplies. The Medical Equipment segment manufactures and sells clinical chemistry analyzer and other products.

2. Method of calculating the amount of sales, profits or losses, assets, liabilities, and other items for each reporting segment

The method of accounting for the reported business segments is "in accordance with the accounting policy adopted to prepare consolidated financial statements".

Profit in the reporting segment is a figure based on operating income.

3 Information on the amount of sales, profits or losses, assets, liabilities and other items for each reported segment, and information on the breakdown of earnings

The previous fiscal year (April 1, 2023 to March 31, 2024)

(in millions of yen)

	Reportable segments				Adjustment amount (Note) 1	Amount recorded in consolidated financial statements (Note)2
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Sales						
Japan	42,406	5,410	12,444	60,262	-	60,262
North, Central, and South America	19,338	3,127	2,349	24,815	-	24,815
China	22,136	10,582	333	33,052	-	33,052
other	36,131	19,889	184	56,206	-	56,206
Revenue generated from customer contracts	120,013	39,010	15,312	174,336	-	174,336
Revenues from external customers	120,013	39,010	15,312	174,336	-	174,336
Transactions with other segments	-	-	-	-	-	-
Total	120,013	39,010	15,312	174,336	-	174,336
Segment Profit	16,845	16,203	475	33,525	(5,993)	27,531
Segment Assets	111,455	59,328	13,717	184,500	45,713	230,213
Other items						
Depreciation	2,887	1,017	359	4,264	385	4,650
Increase in property, plant and equipment and intangible assets	3,042	1,890	247	5,180	379	5,560

Note: 1. The amount of adjustment is as follows.

(1) The adjustment for segment profit of (5,993) million yen includes (5,993) million yen of company-wide expenses that have not been allocated to each reporting segment. Company-wide expenses are mainly related to the Company's general administrative departments, such as the general affairs and accounting departments.

(2) Adjusted segment assets of ¥45,713 million are company-wide assets that have not been allocated to each reporting segment. Company-wide assets consist mainly of residual funds under management (cash and deposits) and long-term investment funds (investment securities).

(3) The adjustment for depreciation and amortization of ¥385 million is a depreciation expense for the Company's General and Administrative Division, which is not attributable to the Reporting Segment.

(4) The adjustment amount of 379 million yen for the increase in property, plant and equipment and intangible assets is a company-wide asset that has not been allocated to each reporting segment.

2. Segment profit is adjusted to operating income in the consolidated statements of income.

The current fiscal year (April 1, 2024 to March 31, 2025)

(in millions of yen)

	Reportable segments				Adjustment amount (Note) 1	Amount recorded in consolidated financial statements (Note)2
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Sales						
Japan	40,356	4,188	12,149	56,693	-	56,693
North, Central, and South America	21,290	4,122	2,755	28,167	-	28,167
China	24,646	19,808	330	44,785	-	44,785
other	38,500	28,363	183	67,047	-	67,047
Revenue generated from customer contracts	124,793	56,483	15,418	196,695	-	196,695
Revenues from external customers	124,793	56,483	15,418	196,695	-	196,695
Transactions with other segments	-	-	-	-	-	-
Total	124,793	56,483	15,418	196,695	-	196,695
Segment Profit	15,017	26,316	662	41,997	(6,495)	35,501
Segment Assets	109,551	51,372	13,909	174,834	47,652	222,486
Other items						
Depreciation	3,012	1,249	325	4,587	337	4,925
Increase in property, plant and equipment and intangible assets	3,750	1,857	235	5,844	1,186	7,030

Note: 1. The amount of adjustment is as follows.

(1) The adjustment for segment profit of (6,495) million yen includes (6,495) million yen of company-wide expenses that have not been allocated to each reporting segment. Company-wide expenses are mainly related to the Company's general administrative departments, such as the general affairs and accounting departments.

(2) Adjusted segment assets of ¥47,652 million are company-wide assets that have not been allocated to each reporting segment. Company-wide assets consist mainly of residual funds under management (cash and deposits) and long-term investment funds (investment securities).

(3) The adjustment for depreciation and amortization of ¥337 million is a depreciation expense for the Company's General and Administrative Division, which is not attributable to the Reporting Segment.

(4) The adjustment amount of 1,186 million yen for the increase in property, plant and equipment and intangible assets is a company-wide asset that has not been allocated to each reporting segment.

2. Segment profit is adjusted to operating income in the consolidated statements of income.

Information on impairment losses on fixed assets by reporting segment

The previous fiscal year (April 1, 2023 to March 31, 2024)

(in millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Impairment losses	603	-	-	603	-	603

The current fiscal year (April 1, 2024 to March 31, 2025)

Not applicable.

Information on amortization and unamortized balances of goodwill by reporting segment

The previous fiscal year (April 1, 2023 to March 31, 2024)

(in millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Depreciation for the period	47	49	-	97	-	97
Balance at the end of the current fiscal year	295	303	-	599	-	599

The current fiscal year (April 1, 2024 to March 31, 2025)

(in millions of yen)

	Reportable segments				Unallocated amounts and elimination	Total
	Scientific and Metrology Instruments	Industrial Equipment	Medical Equipment	Total		
Depreciation for the period	203	49	-	253	-	253
Balance at the end of the current fiscal year	683	228	-	911	-	911